Thrombography;Thrombinographie

Hematologie

Volumn 12, Issue 2, 2006, Pages 115-127

  Lecompte, Thomas ^a,b   Wahl, Denis ^a,b   Regnault, Véronique ^a  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Antiphospholipid; Coagulation; Platelet; Thrombin; Thrombosis

Indexed keywords

PHOSPHOLIPID ANTIBODY; PROTEIN C; THROMBIN;

BLOOD CLOTTING; CLINICAL FEATURE; CLINICAL RESEARCH; DIAGNOSTIC IMAGING; HUMAN; IN VITRO STUDY; PHENOTYPE; RELIABILITY; REVIEW; STANDARDIZATION; THROMBOGRAPHY; THROMBOPHILIA; VALIDATION PROCESS;

EID: 33744826239     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Aiach M. Apport de la génétique moléculaire dans les anomalies responsables de la thrombose. STV 1996; 8: 339-43.
2. Vossen CY, Hasstedt SJ, Rosendaal FR, et al. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J Thromb Haemost 2004; 2: 242-7.
3. Brummel-Ziedins KE, Pouliot RL, Mann KG. Thrombin generation: phenotypic quantitation. J Thromb Haemost 2004; 2: 281-8.
4. Mann KG, Brummel-Ziedins K, Undas A, Butenas S. Does the genotype predict the phenotype? Evaluations of the hemostatic proteome. J Thromb Haemost 2004; 2: 1727-34.
5. Taralunga C, Gueguen R, Visvikis S, et al. Phenotypic sensitivity to activated protein C in healthy families: importance of genetic components and environmental factors. Br J Haematol 2004; 126: 392-7.
6. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-63.
7. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994; 84: 2854-67.
8. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoechiometric regulation of blood coagulation. J Biol Chem 2002; 277: 18322-33.
9. Mannucci PM. The measurement of multifactorial thrombophilia. Thromb Haemost 2002; 88: 1-2; (commentary).
10. Hemker HC, Béguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84: 747-51.
11. Sigaux F. Comment entrer dans l'ère de la biologie intégrative (Systems Biology). Hématologie 2005; 11: 95.
12. Al Dieri R, Peyvandi F, Santagostino E, et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002; 88: 576-82.
13. Bos MHA, Meijerman DWE, van der Zwaan C, Mertens K. Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma? J Thromb Haemost 2005; 3: 522-30.
14. Dargaud Y, Béguin S, Lienhart A, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-80.
15. Mann KG. Thrombin. Can't live without it; probably die from it. Chest 2003; 124: 1S-3S.
16. Di Cera E. Thrombin interactions. Chest 2003; 124: 11S-17S.
17. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23: 17-25.
18. Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol 1974; 27: 517-28.
19. Conde ID, Lopez JA. Pathophysiology of deep venous thrombosis. Hematology (Am Soc Hematol Educ Program) 2004: 439-45; (Am Sc Hematol Educ Program).
20. Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24.
21. Lecut C, Feijge MAH, Cosemans JMEM, Jandrot-Perrus M, Heemskerk JWM. Fibrillar type I collagens enhance platelet-dependent thrombin generation via GP VI with direct support of alpha2-beta1 but not alphaIIb-beta3 integrin. Thromb Haemost 2005; 94: 107-14.
22. Macfarlane RG, Biggs R. A thrombin generation test - The application in haemophilia and thrombocytopenia. J Clin Pathol 1953; 6: 3-8.
23. Pitney WR, Dacie JV. A simple method of studying the generation of thrombin in recalcified plasma - Application in the investigation of haemophilia. J Clin Pathol 1953; 6: 9-14.
24. White GC. The partial thromboplastin time: defining an era in coagulation (historical sketch). J Thromb Haemost 2003; 1: 2267-70.
25. Hemker HC, Al Dieri R, Béguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol 2004; 11: 170-5.
26. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-9.
27. Marder VJ. Maximized hemostasis. Thromb Haemost 2002; 87: 555-6; (commentary).
28. Brinkhous KM. A study of the clotting defect in hemophilia. Am J Med Sci 1939; 198: 509-16.
29. Ginsberg JS, Demers C, Bril-Edwards P, et al. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood 1993; 81: 2958-63.
30. Kyrle PA, Mannhalter C, Béguin S, et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-91.
31. Luddington RJ. Thromboelastography/thromboelastometry. Clin Lab Haematol 2005; 27: 81-90.
32. Rand MD, Lock JB. van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-45.
33. Hemker HC, Giesen PLA, Ramjee M, Wagenvoord R, Béguin S. The thrombogram: monitoring thrombin generation in platelet rich plasma. Thromb Haemost 2000; 83: 589-91.
34. Vanchoonbeek K, Feijge MAH, van Kampen RJW, et al. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2004; 2: 478-84.
35. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
36. Hemker HC, Beguin S. Pourquoi les schémas de coagulation sont faux. STV 1994; 6: 619-25.
37. Cawthern KM. van't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-92.
38. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-52.
39. Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 1989; 61: 25-9.
40. Lawrie AS, Gray E, Leeming D, et al. A multicentre assessment of the endogenous thrombin potential using a continuous monitoring amidolytic technique. J Thromb Haemost 2003(suppl): 1587.
41. Smeets EF, Comfurius P, Bevers EM, Zwaal RFA. Contribution of different phospholipid classes to the prothrombin converting capacity of sonicated lipid vesicles. Thromb Res 1996; 81: 419-26.
42. Regnault V, Béguin S, Lecompte T. Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability. Pathophysiol Haemost Thromb 2003; 33: 23-9.
43. Regnault V, Boehlen F, Ozsahin H, et al. Anti-protein S antibodies following a varicella infection: detection, characterization and influence on thrombin generation. J Thromb Haemost 2005; 3: 1243-9.
44. Wagenvoord R, Hendrix HH, Kai U, Hemker HC. A chromogenic test to determine the procoagulant phospholipids in platelet-rich plasma and whole blood. Thromb Haemost 1994; 72: 582-7.
45. Jane SM, Mitchell CA, Hau L, Salem HH. Inhibition of activated protein C in platelets. J Clin Invest 1989; 83: 222-6.
46. Taube J, McWilliam N, Luddington R, Byrne C, Baglin T. Activated protein C resistance: effect of platelet activation, platelet-derived microparticles, and atherogenic lipoproteins. Blood 1999; 93: 3792-7.
47. Nishioka J, Ning M, Hayashi T, Suzuki K. Protein C inhibitor secreted from activated platelets efficiently inhibits activated protein C on phosphatidylethanolamine of platelet membrane and microvesides. J Biol Chem 1998: 11281-7.
48. Mohri M, Suzuki M, Sugimoto E, Sata M, Yamamoto S, Maruyama I. Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma. Thromb Haemost 1998; 80: 925-9.
49. Taylor FB, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001; 97: 1685-8.
50. Regnault V, de Maistre E, Geschier C, Briquel ME, André E, Stoltz JF, Lecompte T. A new fast one-step immunopreparation for activated protein C. Thromb Haemost 1995; 73: 1365.
51. Alhenc-Gelas M, Plu-Bureau G, Guillonneau S, et al. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost 2004; 2: 1594-600.
52. de Visser MCH, van Hylckama Vlieg A, Tans G, et al. Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost 2005; 3: 1488-94.
53. Al Dieri R, Wagenvoord R, van Deden GWK, Béguin S, Hemker HC. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif - the C-domain. J Thromb Haemost 2003; 1: 907-14.
54. Al Dieri R, Alban S, Béguin S, Hemker HC. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004; 2: 1395-401.
55. Béguin S, Keularts I, Al Dieri R, Bellucci S, Caen J, Hemker HC. Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a vWF-GPIb-dependent process, defective in Bernard-Soulier syndrome. J Thromb Haemost 2004; 2: 170-6.
56. Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996; 98: 863-74.
57. Keularts IM, Béguin S, de Zwaan C, Hemker HC. Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients Thromb Haemost 1998; 80: 370-1.
58. Regnault V, Briquel ME, Nguyen P, et al. Thrombinography can differentiate bleeding from non-bleeding patients with prolonged APTT. J Thromb Haemost 2003(suppl): 1585.
59. Beltran-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005; 11: 326-34.
60. Olson JD. College of American Pathologists consensus conference XXXVI: diagnostic issues in thrombophilia. Arch Pathol Lab Med 2001; 126: 1277-80.
61. Wielders S, Mukherjee M, Michiels J, et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997; 77: 629-36.
62. Curvers J, Thomassen MCLGD, Rimmer J, et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002; 88: 5-11.
63. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
64. Ceelie H, Spaargaren-van Riel CC, Bertina RM, Vos HL. G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3′-end formation. J Thromb Haemost 2003; 2: 119-27.
65. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
66. Vossen CY, Conard J, Fontcuberta J, et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost 2004; 2: 1526-32.
67. Kearon C. Risk factors for recurrent venous thromboembolism and their implications for treatment. Hematology (Am Soc Hematol Educ Program) 2004: 445-9; (Am Sc Hematol Educ Program).
68. 2-glycoprotein I increase the risk of recurrent venous thromboembolism in patients without systemic lupus erythematosus. QJM 1998; 91: 125-30.
69. Regnault V, Béguin S, Wahl D, De Maistre E, Membré A, Hemker HC, Lecompte T. Increased thrombin potential due to acquired activated protein C resistance in patients with lupus anticoagulants. J Thromb Haemost 2003: P1536.
70. Dahlbäck B, Nilsson IM, Frohm B. Inhibition of platelet prothrombinase activity by a lupus anticoagulant. Blood 1983; 62: 218-25.
71. Regnault V, Hemker HC, Wahl D, Lecompte T. Phenotyping ths haemostatic system by thrombography - potential for the estimation of thrombotic risk. Thromb Res 2004; 114: 539-45.
72. 2-glycoprotein I induced acquired activated protein C resistance evidenced by calibrated automated thrombography. J Thromb Haemost 2005(suppl): 19.
73. Rosing J, Tans G. Coagulation factor V: an old star shines again. Thromb Haemost 1997; 78: 427-33.
74. Dahlbäck B. Procoagulant and anticoagulant properties of coagulation factor V: factor V Leiden (APC resistance) causes hypercoagulability by dual mechanisms. J Lab Clin Med 1999; 133: 415-22.
75. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81: 2618-25.
76. Guermazi S, Regnault V, Gorgi Y, Ayed K, Lecompte T, Dellagi K. Further evidence for the presence of anti-protein S autoantibodies in patients with systemic lupus erythematosus. Blood Coagul Fibrinolysis 2000; 11: 491-8.
77. Regnault V, de Moerloose P, Rivalan J, Pommereuil M, Wahl D, de Groot PG, Lecompte T. Insensitivity of thrombin potential to activated protein C due to antibody-mediated qualitative or quantitative protein S deficiencies. J Thromb Haemost 2005; 3(suppl 1): OR294.
78. Magid E. Minimal requirements for test evaluation. Scand J Clin Lab Invest 1997; 57: 90-4.
79. Bossuyt PMM, Lijmer JG, Mol BWJ. Randomised comparisons of medical tests: sometimes invalid, not always efficient. Lancet 2000; 356: 1844-7.
80. Lecompte T, Carteaux JP, Regnault V, de Maistre E, Collet JY, Villemot JP. Is it possible and worth to use another anticoagulant than (unfractionated) heparin during cardiopulmonary bypass for cardiac surgery? ITBM-RBM 2003; 24: 45s-53s.